Overview

Nplex Biosciences develops advanced solutions for protein measurement in the biotechnology sector, focusing on proteomics using nanotechnology. Their main product, the nELISA, is a compact and efficient version of the traditional sandwich ELISA immunoassay, allowing for the simultaneous analysis of multiple proteins in a cost-effective manner. This platform addresses previous economic challenges in antibody-based proteomics, making it accessible for various research teams in academic, pharmaceutical, and biotech settings. Nplex Biosciences differentiates itself by utilizing DNA nanotechnology to enhance the accuracy and efficiency of protein analysis on small beads. The company's goal is to provide a scalable and reliable proteomics platform that supports high-throughput needs in drug discovery, biomarker discovery, and personalized medicine.

Simplify's Take

What believers are saying

• Nomic secured $42M in Series B funding to expand protein profiling capabilities.
• The rise of personalized medicine increases demand for high-throughput proteomics solutions.
• Global proteomics market projected to grow at 14.1% CAGR from 2023 to 2028.

What critics are saying

• Emerging competition from SomaLogic and Olink may impact Nomic's market share.
• Rapid technological advancements could render Nomic's platform obsolete without continuous innovation.
• Supply chain vulnerabilities in nanotechnology components could disrupt production schedules.

What makes Nomic unique

• Nomic's nELISA platform offers scalable, cost-effective protein measurement solutions.
• The company leverages DNA nanotechnology for precise protein analysis on micron-sized beads.
• Nomic serves high-throughput needs in drug discovery and personalized medicine sectors.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$60M

Above

Industry Average

Funded Over

3 Rounds

$42,000,000

Series B

Sep 2024

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Above Average

Industry standards

Ind Avg. $35M

$4M

$30M

$42M

$45M

$65M

$100M

View all funding stages